01.31.25 -- Regulatory T Cells & Autoimmune Disease

Why are ophthalmic assessments increasingly vital in non-ophthalmic clinical trials? Learn more about the key challenges non-ophthalmic trials face and how to proactively mitigate risk.

Through this workshop, participants will gain insights into the development and evaluation of ADCs, from preclinical research to manufacturing intricacies (CMC) and clinical advancements.

Failing to recruit and retain patients results in 86% of all trials not meeting their enrollment deadlines and 30% of Phase III trials fail –ultimately driving up costs and risk.

For APAC companies, it's important to identify the differences in care standards, formulate strategies for compliance, and develop solutions to bridge the regulatory gap and realize FDA approval.

Building an "analytics culture" in clinical research requires striking a balance between fast, flexible technologies and the right support for trial teams working to integrate these solutions.

Here we highlight key advantages of EHR-to-EDC eSource, such as cost-effectiveness and improved site satisfaction.